Auto-antibody Studies in Interstitial Pulmonary Fibrosis
Related Articles
- Pulmonary Toxicity Associated with Bischloroethylnitrosourea (BCNU). Durant, John R.; Norgard, Michael J.; Murad, Tariq M.; Bartolucci, Alfred A.; Langford, Keith H. // Annals of Internal Medicine;Feb79, Vol. 90 Issue 2, p191
Describes the cases of pulmonary toxicity secondary to bischloroethylnitrosourea administration. Classes of antineoplastic chemotherapeutic agents; Overview of pulmonary function studies and response to therapy; Information on focal interstitial fibrosis.
- Chronic Interstitial Lung Disease. Hilman, Bettina C. // Clinical Pediatrics;Nov1998, Vol. 37 Issue 11, p701
Editorial. Deals with chronic interstitial lung disease (ILD). Characteristics of interstitial pulmonary fibrosis; Utilization of glucocorticosteroids in the treatment of ILD.
- Pulmonary fibrosis—an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis? Bhanji, Amir; Karim, Mahzuz // NDT Plus;Aug2010, Vol. 3 Issue 4, p351
Small vessel vasculitides such as microscopic polyangiitis and Wegener’s granulomatosis commonly involve the kidney and lung, with alveolar haemorrhage being the commonest manifestation of pulmonary involvement. Here we describe a patient who developed acute renal failure and pulmonary...
- Interstitial lung disease: clinical. // Thorax;Dec2013 Supplement, Vol. 68 Issue S3, pA9
The article presents abstracts on topics related to idiopathic pulmonary fibrosis (IPF) which include multidisciplinary discussion on interstitial lung disease, use of forced vital capacity in lung disease idiopathic pulmonary fibrosis patients and study results on IPF patients using placebos.
- Paclitaxel. // Reactions Weekly;6/10/2006, Issue 1105, p14
The article presents a case study of a 62-year-old woman with a history of tonsillectomy and pneumonia who died as a result of developing interstitial pneumonitis and pulmonary fibrosis after treatment with paclitaxel for advanced ovarian cancer.
- The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Yousem, Samuel A; Gibson, Kevin; Kaminski, Naftali; Oddis, Chester V; Ascherman, Dana P // Modern Pathology;Jun2010, Vol. 23 Issue 6, p874
No abstract available.
- Clinical and basic science of interstitial lung disease. // Thorax;Dec2006 Supplement 2, Vol. 61, pii37
The article presents abstracts of medical research about clinical and basic science of interstitial lung disease. They include "Autoantibody Profile Rather Than Extent of Skin Disease Predicts Severity of Pulmonary Fibrosis in Systemic Sclerosis," "T-Bet Expression in Bronchoalveolar Lavage...
- Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan. Haibo Huang; Xiaonu Peng; Nakajima, Jun // BioScience Trends;Aug2013, Vol. 7 Issue 4, p172
Idiopathic pulmonary fibrosis is an intractable disease with a median survival time of 2 to 3 years. Serum levels of Krebs von den Lungen-6 (KL-6), surfactant protein A (SP-A), and surfactant protein D (SP-D) are useful biomarkers for idiopathic pulmonary fibrosis and they are widely used in...
- Therapeutic Plasma Changes Help IPF Patients. // AARC Times;Oct2015, Vol. 39 Issue 10, p67
The article reviews a U.S. study conducted by Steve Duncan and colleagues and published in a 2015 issue of the "PLOS ONE" journal which reported promising results for patients suffering from exacerbation of idiopathic pulmonary fibrosis (IPF) who are treated with autoantibody-targeted therapies.
- FIBROSIS. // Current Medical Literature: Respiratory Medicine;2005, Vol. 19 Issue 4, p100
Presents abstracts of several studies related to fibrosis. "Interferon-y1b Therapy in Idiopathic Pulmonary Fibrosis: A Metaanalysis," by E. K. Bajwa, N. T. Ayas and M. Schulzer; "Double-Blind, Placebo-Controlled Trial of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis," by A. Azuma,...
